Research Highlights Fat stored around the waist, often called belly fat or visceral fat, showed a much stronger link to heart ...

The CHARM program consisted of 3 component trials, each comparing candesartan with placebo in a distinct population of patients with symptomatic heart failure [9]: CHARM-Alternative: patients with ...

Research presented at the American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, found that the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) was able to assess patients’ ...

Please provide your email address to receive an email when new articles are posted on . CAD was significantly prognostic of all-cause mortality in patients with heart failure. Mortality risk was ...

Applying artificial intelligence techniques to cardiac ultrasound data may make it easier to identify patients with advanced heart failure, a new ...

A novel risk calculator integrating comorbidities and gut-derived biomarkers stratifies risk of rehospitalisation and death in heart failure.

Adjusted analyses associated overestimation with nearly doubled 2-year mortality (aHR 1.98; 95% CI, 1.04-3.77). Differences in advanced-therapy receipt did not explain the mortality signal, suggesting ...

NEW ORLEANS , LA, UNITED STATES, March 19, 2026 /EINPresswire.com/ -- HeartLung.AI today announced that it will ...

Oral semaglutide reduces risk for heart failure events among patients with T2D and preexisting heart failure, according to the SOUL trial.

An innovative stem cell therapy approved for severe heart failure has been cleared for use in Japan. Here is why it matters ...